Literature DB >> 16413103

The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.

Felix K-H Chun1, Alberto Briganti, Thierry Lebeau, Vincent Fradet, Thomas Steuber, Jochen Walz, Thorsten Schlomm, Christian Eichelberg, Alexander Haese, Andreas Erbersdobler, Michael McCormack, Paul Perrotte, Markus Graefen, Hartwig Huland, Pierre I Karakiewicz.   

Abstract

INTRODUCTION: We examined the prognostic value of AJCC pT2 substages in prediction of biochemical recurrence (BCR) after radical prostatectomy (RP), in European patients.
METHODS: A cohort of 1726 RP patients with pT2N0 prostate cancer (PCa) was studied. Multivariate Cox regression models addressed the association between either the 1997 or 1992/2002 pT2 substages after controlling for total PSA, primary and secondary pathologic Gleason scores and surgical margin status and time to PSA recurrence (PSA >0.1 and rising) after RP. Regression coefficients were then used to test the predictive accuracy of multivariate models in a nomogram setting.
RESULTS: PSA recurrence occurred in 80 (4.6%) patients. Mean and median times to recurrence were respectively 28.9 and 24.4 months. In univariate analyses, neither the 1997 (p = 0.48) nor the 1992/2002 pT2 substages (p = 0.054) were predictive of recurrence. In multivariate analyses the lack of significance persisted (1997 p = 0.709; 1992/2002 p = 0.124). When either the 1997 or 1992/2002 pT2 substages were added to a multivariate nomogram without pT2 substage information, its accuracy respectively decreased by 0.8% and 1.1%.
CONCLUSION: Our data indicate that pT2 substages offer no incremental value relative to pre-treatment total PSA, surgical margin status and pathologic Gleason scores. Therefore, it might be postulated that it is sufficient to confirm organ confinement according to Partin's pathologic staging.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413103     DOI: 10.1016/j.eururo.2005.12.009

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

1.  Total intraglandular and index tumor volumes predict biochemical recurrence in prostate cancer.

Authors:  Su-Jin Shin; Cheol Keun Park; Sung Yoon Park; Won Sik Jang; Joo Yong Lee; Young Deuk Choi; Nam Hoon Cho
Journal:  Virchows Arch       Date:  2016-06-15       Impact factor: 4.064

2.  In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence.

Authors:  Yujiro Ito; Emily A Vertosick; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; Sahussapont J Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

3.  Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Mark K Buyyounouski; Peter L Choyke; Jesse K McKenney; Oliver Sartor; Howard M Sandler; Mahul B Amin; Michael W Kattan; Daniel W Lin
Journal:  CA Cancer J Clin       Date:  2017-02-21       Impact factor: 508.702

4.  Should pathologists continue to use the current pT2 substaging system for reporting of radical prostatectomy specimens?

Authors:  Athanase Billis; Luciana L Meirelles; Leandro L L Freitas; Luis A Magna; Leonardo O Reis; Ubirajara Ferreira
Journal:  Int Urol Nephrol       Date:  2011-02-20       Impact factor: 2.370

5.  Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer.

Authors:  Wen-Jun Xiao; Yu Zhu; Yao Zhu; Bo Dai; Ding-Wei Ye
Journal:  World J Urol       Date:  2018-01-25       Impact factor: 4.226

6.  Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy.

Authors:  Wen-Jun Xiao; Yao Zhu; Bo Dai; Ding-Wei Ye
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.